The Melanoma Program (MEL) carries out impactful research aimed at improving patient outcomes by understanding melanoma biology and addressing unmet needs in melanoma management. This effort is facilitated by one of the nation?s oldest and largest biobanks of melanoma specimens, linked to prospective, and protocol-driven clinical information for more than 3,700 patients. Special areas of interest include: better stratification of recurrence risk after primary treatment, improved decision making for adjuvant treatment of those at high risk of recurrence, identification of the molecular drivers of melanoma progression with a particular focus on brain tropism, and developing new therapies for patients with advanced melanoma. Led by Iman Osman, MD and Jeffrey Weber, MD PhD, MEL comprises a multi-disciplinary team of 21 members representing 12 departments at NYU School of Medicine and other NYU colleges that advances basic science, translational and clinical melanoma research. Six new members filled strategic needs, and have advanced our goal of bringing novel therapeutics into the clinic. MEL has also significantly enhanced its research and outreach targeting the PCC catchment area with a new effort on acral melanoma, which disportionately affects African Americans and Hispanics. Since the last CCSG review, our NCI funding has nearly tripled from $729K to $2.1 million, while overall cancer-related funding has almost doubled from $3.4 to $6.03 million. Members published 354 papers, with 31% of the citations appearing in journals with IF>10. Members are highly collaborative: 19% of publications are intra-programmatic, 31% of publications are intra- programmatic, and 35% are inter-institutional (with NCI-CCs). During this funding period, MEL members made major strides in understanding the melanoma cell-of-origin and the mechanisms driving metastatic progression. We have focused our attention on downstream epigenetic and transcriptional programs, some that are directly ?druggable? (i.e., BRD4); others that indirectly result in emergence of novel targets (e.g., HSF1, AMIGO2, FUT8, PTK7). MEL co-leaders and several of its senior members recently submitted a SPORE application, which received a high impact score and will be resubmitted in May 2018. Our scientific goals are organized around three complementary thematic aims:
Aim 1 : To identify novel prognostic and predictive molecular biomarker(s) of melanoma progression and response to therapy, Aim 2: To understand the biologic heterogeneity of melanoma at the molecular level, and Aim 3: To develop new treatments that overcome therapeutic resistance. MEL promotes the PCC mission to improve cancer treatment, outcome, and quality of life for patients by: (1) accruing patients to high quality, investigator-initiated trials, (2) expanding a large melanoma biobank tied to clinical information, (3) pursuing science that informs patient stratification for personalized treatment, and (4) developing new approaches to detection, early intervention and treatment of advanced disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016087-40
Application #
10124329
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-12-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
40
Fiscal Year
2021
Total Cost
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Taylor, Martin S; Altukhov, Ilya; Molloy, Kelly R et al. (2018) Dissection of affinity captured LINE-1 macromolecular complexes. Elife 7:
Bertrand, Anne; Baron, Maria; Hoang, Dung M et al. (2018) In Vivo Evaluation of Neuronal Transport in Murine Models of Neurodegeneration Using Manganese-Enhanced MRI. Methods Mol Biol 1779:527-541
Jung, Seungyoun; Allen, Naomi; Arslan, Alan A et al. (2018) Anti-M├╝llerian hormone and risk of ovarian cancer in nine cohorts. Int J Cancer 142:262-270
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Kirkling, Margaret E; Cytlak, Urszula; Lau, Colleen M et al. (2018) Notch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic Cells. Cell Rep 23:3658-3672.e6
Gong, Yixiao; Lazaris, Charalampos; Sakellaropoulos, Theodore et al. (2018) Stratification of TAD boundaries reveals preferential insulation of super-enhancers by strong boundaries. Nat Commun 9:542
Hadi, Tarik; Boytard, Ludovic; Silvestro, Michele et al. (2018) Macrophage-derived netrin-1 promotes abdominal aortic aneurysm formation by activating MMP3 in vascular smooth muscle cells. Nat Commun 9:5022
Minton, Denise R; Nam, Minwoo; McLaughlin, Daniel J et al. (2018) Serine Catabolism by SHMT2 Is Required for Proper Mitochondrial Translation Initiation and Maintenance of Formylmethionyl-tRNAs. Mol Cell 69:610-621.e5
Lim, Chae Ho; Sun, Qi; Ratti, Karan et al. (2018) Hedgehog stimulates hair follicle neogenesis by creating inductive dermis during murine skin wound healing. Nat Commun 9:4903
Zhang, Yilong; Shao, Yongzhao (2018) Concordance measure and discriminatory accuracy in transformation cure models. Biostatistics 19:14-26

Showing the most recent 10 out of 1170 publications